FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (prostate cancer) as Merck Sharp & Dohme LLC.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Prostate Cancer
- Sub-indication
- Prostate Cancer
Related signal: Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival